Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

Changes in the business of culture

Nature Biotechnology volume 22, pages 1355–1356 (2004)Cite this article

Supply and demand

Biologics represented 53% of the new molecular entities approved by the US Food and Drug Administration (Rockville, MD, USA) in 2002 (ref. 1). About 35 biopharmaceutical products are currently on the market, and an estimated 700 or more protein-based therapeutics are at various stages of clinical development, with 150 to 200 in late-stage trials1. It is estimated that as many as 40 new biopharmaceutical products could be approved by 2005–2006, with the biologics market reaching $70 billion or 12% of the pharmaceutical market1. Although the majority of this growth will come from recombinant proteins, a modest amount will also come from peptides produced synthetically. Overall, the global market for contract biomanufacturing reached $1.3 billion in 2003. It is expected to reach $3.7 billion by 2010, increasing at a compound annual growth rate of approximately 14%1.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Bob Crimi

References

  1. Anscomb, A. Pharmaceutical outsourcing opportunities post launch. in Kalorama Information Market Intelligence (ed. Heffner, S.) (New York, 2004).

    Google Scholar 

  2. Bioprocess International. Protein Expression in the 21st Century. Bioprocess International Supplement Series (Bioprocess International, Eugene, OR, 2004).

  3. Mallik, A. et al. in Mckinsey Quarterly 2002 Special Edition: Risk and Resilience. 9–11 (McKinsey, New York, 2002).

    Google Scholar 

  4. European Parliament and European Council. Off. J. Eur. Commun. L121, 34–44 (2001).

  5. Usdin, S. BioCentury August 2, A1–A10 (2004).

  6. Gross, A. Bioprocess International 2, 26–30 (2004).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Biotecnol SA, Taguspark, Edifício Inovação 4, No. 809, Oeiras, 2780-920, Portugal

    Pedro de Noronha Pissarra

Authors
  1. Pedro de Noronha Pissarra
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Noronha Pissarra, P. Changes in the business of culture. Nat Biotechnol 22, 1355–1356 (2004). https://doi.org/10.1038/nbt1104-1355

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1104-1355

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing